Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
RESEARCH TOOLSreports
ORIC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.33 - $16.65
Previous CloseN/A
Volume181.02K
Average Volume (3M)532.15K
Market Cap
$728.96M
Enterprise Value$453.81M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Mar 25, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding70,566,950
10 Day Avg. Volume665,520
30 Day Avg. Volume532,147
Standard Deviation0.25
R-Squared0.05
Alpha-0.00880
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-439.74
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$18.00Price Target Upside60.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Earnings PotentialORIC Pharmaceuticals has projected probability-adjusted worldwide peak sales of approximately $575 million in metastatic castration-resistant prostate cancer.
Management ExpertiseORIC has a highly experienced management team with a successful track record developing entrectinib at Ignyta.
Safety ProfileORIC's '944 + Erleada combo data showed markedly better safety profile.
Bears Say
Clinical TrialsThe bar for Pfizer's mevrometostat is considered to be a hazard ratio of less than 0.70 and showing a progression-free survival benefit of more than 30% with mevrometostat + Xtandi over Xtandi alone.
Market CompetitionThere are clear signs of differentiation in ORIC's development plan with specificity, breadth of mutation coverage, and safety profile in a crowded EGFR/HER2 space in NSCLC.
Regulatory ChallengesPotential accelerated approval for ORIC-114 in non-small cell lung cancer could be on the horizon, based on broad activity data expected in the upcoming clinical updates.
---
Ownership Overview
17.57% Insiders
11.83% Mutual Funds
0.26% Other Institutional Investors
59.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $6.33 and its highest was $16.65 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $728.96M.
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is Mar 25, 2025 which is in 42 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.012.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 70,566,950 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went up 0.097%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Currently, no hedge funds are holding shares in ORIC
---
Oric Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (60.28% Upside)
$18.00 (60.28% Upside)
Blogger Sentiment
Bullish
ORIC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 82.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.09%
12-Months-Change
Fundamentals
Return on Equity
-45.98%
Trailing 12-Months
Asset Growth
10.11%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
---
ORIC Stock 12 Month Forecast
Average Price Target
$18.00
▲(60.28% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Zai Lab
―
Krystal Biotech
―
Replimune Group
―
Best Analysts Covering ORIC
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+33.09%
reiterated a buy rating 2 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +33.09% per trade.
---